Xuanzhu Biopharmaceutical Co., Ltd. released its first Environmental, Social and Governance (ESG) report covering the 2025 fiscal year. The document outlines governance enhancements, climate-related disclosures, responsible product practices and workforce initiatives while providing detailed quantitative metrics.
Governance and strategy • A three-tier ESG structure—Board, management and working group—oversees materiality, risk and disclosure. • Climate oversight aligns with this framework; scenario analysis based on IPCC SSP5-8.5 and IEA NZE models found no high-level risks but identified acute physical threats (floods, cold waves) and transition pressures (stricter policies, rising raw-material costs). • Electricity-use reduction of 5 % versus 2023 was achieved, aided by office energy audits and equipment upgrades.
Environmental performance • Scope 1 emissions were 12.74 tCO₂e; Scope 2 (location-based) reached 1,224.63 tCO₂e, bringing Scope 1-2 total to 1,237.37 tCO₂e. • Scope 3 (business travel and paper) added 212.02 tCO₂e. • Total energy consumption stood at 2.01 million kWh, of which 1.52 million kWh were electricity and 476.69 thousand kWh purchased heat. • Wastewater discharge was 7,052 tonnes; hazardous waste generation was 2.56 tonnes, and non-hazardous waste 9.97 tonnes. • Company-wide safety record showed zero work-related fatalities or lost-day injuries.
Innovation and product responsibility • R&D expenditure reached RMB 183.84 million in 2025. • Three Class 1 innovative drugs have obtained China NMPA approval: – Anaprazole Sodium (An Jiu Wei) for duodenal ulcer, already listed in the National Reimbursement Drug List (NRDL). – Bireociclib (Xuan Yue Ning), a CDK 2/4/6 inhibitor, now covers first-, second- and later-line HR+/HER2- advanced breast cancer. – Dirozalkib (Xuan Fei Ning), an ALK inhibitor targeting advanced NSCLC. • The pipeline exceeds ten active assets, including ADC candidate KM501 in Phase I. • Quality management follows GMP/GLP/GCP standards; only five adverse-reaction reports were recorded in 2025.
Workforce and talent • Headcount totalled 342, with women representing 39 %. • Average training hours reached 7.36 for men and 9.09 for women; overall training coverage exceeded 90 %. • No child or forced labour cases were identified. • Employee turnover rate was 14.54 % in China; overall male turnover was 11.49 %, female 19.28 %.
Compliance and supply chain • Anti-bribery, whistle-blower protection and 360° supplier assessments are in place; no corruption litigation occurred during the year. • Supplier base counts 201 entities, 97 of which are in East China; all sign integrity agreements. • Hazardous-waste and special-equipment safety trainings were delivered to all staff.
Community and access • Two innovative drugs—Anaprazole Sodium and Bireociclib—are listed in the NRDL, improving affordability and access. • The company contributed to industry knowledge at BIOCHINA 2025, sharing clinical data on Bireociclib.
The report received Board approval on 30 March 2026 and is available in Chinese and English on both the company and HKEX websites.